EUCTR2019-000638-20-ESActive, not recruitingPhase 1
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus
AbbVie Deutschland GmbH & Co. KG0 sites325 target enrollmentStarted: September 27, 2019Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 325
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •Adult male or female, 18 -65 years of age, inclusive, at Screening
- •SLE by ACR 2012 or SLICC Diagnostic Criteria
- •At Screening, must have at least one of the following:
- •· ANA+ (titer = 1:80)
- •· anti-dsDNA+
- •· anti-Smith+
- •SLEDAI-2K = 6 despite background therapy as reported and independently adjudicated (excluding lupus headache and/or organic brain syndrome) (clinical score = 4) at Screening. If 4 points of the required entry points are for arthritis there must also be a minimum of 3 tender and 3 swollen joints
- •Background treatment, stable for 30 days, with prednisone (=20mg), antimalarials, azathioprine (= 150mg), mycophenolate (= 2g), leflunomide (= 20mg) and/or methotrexate (MTX) (= 20mg), cyclosporine, tacrolimus;
- •The combination of background treatment with antimalarial(s) and/or prednisone (or equivalent) and a single, but not multiple, additional immunosuppressant is permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 315
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
- •Women of childbearing potential must not have a positive serum pregnancy test at the screening visit and must have a negative urine pregnancy test at baseline prior to the first dose of study drug. Note: Subjects with borderline serum pregnancy tests at Screening must have a serum pregnancy test = 3 days later to document continued lack of positive result.
- •Must not be using IV or IM corticosteroids greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days weeks of planned randomization
- •Must not have active lupus nephritis (progressive Class IV or >1g/d proteinuria) or have undergone induction therapy within the last 6 months.
- •Must not have active neuropsychiatric SLE as defined by the CNS portion of SLEDAI-2K (excluding lupus headache).
- •Subjects must be naïve or have discontinued, if not currently benefiting from, the following prior to the first dose of study drug per the applicable washout period below or should be at least 5 times the mean terminal elimination half-life of a drug:
- •· =6 months for Plasmapheresis
- •· =3 months for Benlysta
- •· =1 year for rituximab OR = 6 months if B cells have returned to = 50 B cells per microliter
- •· =3 months for cyclophosphamide
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 2 study to investigate the safety and efficacy of ABBV-105 given alone or in combination with ABT-494 (Upadacitinib) in patients with active rheumatoid arthritis who have failed prior treatment with biologic therapyRheumatoid ArthritisEUCTR2018-000666-10-HUAbbVie Deutschland GmbH & Co. KG240
Active, not recruiting
Phase 1
A Phase 2 study to investigate the safety and efficacy of ABBV-105 given alone or in combination with ABT-494 (Upadacitinib) in patients with active rheumatoid arthritis who have failed prior treatment with biologic therapyMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Rheumatoid ArthritisEUCTR2018-000666-10-GBAbbVie Deutschland GmbH & Co. KG240
Active, not recruiting
Phase 1
A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateRheumatoid ArthritisMedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-004019-37-DKAbbVie Deutschland GmbH & Co. KG222
Active, not recruiting
Phase 1
A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateMedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-004019-37-CZAbbVie Deutschland GmbH & Co. KG222
Active, not recruiting
Phase 1
A Phase 2 study to investigate the safety and efficacy of ABBV-105 given alone or in combination with ABT-494 (Upadacitinib) in patients with active rheumatoid arthritis who have failed prior treatment with biologic therapyMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Rheumatoid ArthritisEUCTR2018-000666-10-ESAbbVie Deutschland GmbH & Co. KG240